ArticlePloS one2016
Underweight Is an Independent Risk Factor for Renal Function Deterioration in Patients with IgA Nephropathy.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Risk Factors of Disease Progression in IgA Nephropathy: A Systematic Review and Meta-Analysis.Immunity, inflammation and disease · 2026Pooled it
- Visceral Obesity and Metabolic Dysfunction in IgA Nephropathy: Nutritional and Metabolic Perspectives on Disease Progression.Nutrients · 2025Pooled it
- Impact of body mass index on primary immunoglobulin A nephropathy prognosis: a systematic review and meta-analysis.International urology and nephrology · 2022Pooled it
- A Rare Genetic Defect ofFrontiers in immunology · 2019Trial
- Thickening of Glomerular Basement Membrane Is Associated with Long-Term Prognosis in Patients with IgA Nephropathy.Kidney360 · 2026Article
- Non-linear relationship between BMI and eGFR at admission in elderly patients with hip fractures: a retrospective cross-sectional study.BMC geriatrics · 2026Article
- Review
- Association between prognostic nutritional index and complications in children with immunoglobulin A vasculitis.Frontiers in nutrition · 2026Article
- Article
- Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy.Renal failure · 2025Article
- Causal associations between environmental factors and risk of IgA nephropathy and membranous nephropathy: a bidirectional Mendelian randomization and mediation analysis.Renal failure · 2025Article
- Prognostic nutritional index as an independent risk factor for disease progression in patients with IgA nephropathy.Frontiers in medicine · 2025Article
- Development of risk models for early detection and prediction of chronic kidney disease in clinical settings.Scientific reports · 2024Article
- The impact of metabolic component count on IgA nephropathy prognosis.Scientific reports · 2024Article
- Prevalence and predictors for cisplatin-induced toxicities in Zimbabwean women with cervical cancer.Future oncology (London, England) · 2024Article
- The Impact of BMI Changes on the Incidence of Glomerular Hematuria in Korean Adults: A Retrospective Study Based on the NHIS-HEALS Cohort.Biomedicines · 2023Article
- Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases.Frontiers in pharmacology · 2022Review
- Correlation of Body Mass Index with Clinicopathologic Parameters in Patients with Idiopathic Membranous Nephropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Population Estimates of GFR and Risk Factors for CKD in Guatemala.Kidney international reports · 2021Article
- Increased Lifetime Risk of ESRD in Familial IgA Nephropathy.Kidney international reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies on the relationship between body mass index (BMI) and renal progression in IgA Nephropathy (IgAN) were limited, especially for underweight patients with IgAN. To elucidate the clinical features and effect of underweight on renal function deterioration in this disease, we recruited IgAN patients with diagnostic age ≥18 years old and a baseline estimated glomerular filtration rate (eGFR) ≥15 ml/min/1.73m2 from our center between 1985 and 2014. Patients secondary to systemic diseases or follow-up less than 6 months were excluded. All patients' clinical data at renal biopsy and during follow-up were recorded. Renal outcome was defined as end-stage kidney disease (ESRD). Baseline body mass index (BMI) was calculated by weight (kg) over squared height (m2). According to WHO Asian guideline, BMI was categorized as follows: <18.5kg/m2 (underweight), 18.5-22.99kg/m2 (normal weight), 23-27.49kg/m2 (overweight) and obese (≥27.5 kg/m2). Of 930 primary IgAN patients enrolled in this study, mean age at renal biopsy was 37.6 years and 49.2% were men. Totally, 114 (12.3%) ESRD occurred after a mean follow-up of 47.1 months. More ESRD happened in underweight patients (17.3%) compared to patients with normal weight (13.2%), overweight (11.0%) or obesity (9.5%). By multivariate Cox regression analysis, underweight was independently associated with a higher risk of ESRD after adjustment for demographic characteristics and clinical variables (HR: 3.5, 95% CI: 1.3-9.5, P = 0.01) comparing to normal weight. Underweight patients had lower hemoglobin, serum uric acid, triglycerides, cholesterol and lymphocyte counts than patients with normal weight. Furthermore, BMI was positively correlated with serum C3 (r = 0.25, p <0.001). Our research finds that underweight is an independent risk factor for kidney disease progression in IgAN, which might be associated with malnutrition status and decreased C3 levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.